HIMS & HERS (To himMillennial-SKEWED Telehealth Company has seen that stocks fall almost 9% on Tuesday as they stop the change in regulatory changes in the weight loss pharmaceutical industry on Tuesday.
HIMS Stock was hit one day after the US Food and Drug Administration (FDA). I updated the page on the website Briefly explain concerns about the use of “unlawful GLP-1 drugs.” GLP-1 drugs are Novo Nordisk ‘S (Ngo) Ozempic that imitates hormones that control blood sugar and suppress appetite.
The FDA warns that the use of unlawful versions of these drugs, including the composite version on Monday, said that it could be dangerous for the patient because it was not reviewed by the FDA on safety, effects and quality before the unauthorized version is sold.
In May, he and she started selling Complex Semaglu Tide The active ingredient of Ozempic and Wegovy of Novo Nordisk is $ 199 a month. It is a big difference compared to the $ 1,000 of Ozempic and the $ 1,349 price tag of WEGOVY. Complex means that pharmacies or doctors customize drugs approved by the needs of individual patients. The company’s total sales increased to $ 1.5 billion last year, up 69%.
HIMS & HERS has recently been able to sell this brand version due to the lack of GLP-1 drugs. In general, food, drugs and cosmetic behaviors are prohibited to create drugs, which are drugs of commercially available drugs. However, if the drug is insufficient, the US Food and Drug Administration (FDA) is not considered commercially available.
Now this is Ozempic The tribe is overHIMS & HERS should stop selling the “essential copy” of the complex Semagluide this year.
The FDA said it will cite a company and medical service providers that continue to provide a “required copy” of the judge rules of judges (what comes later) of the Industry Group Outsourcing Faciltionities Association.
When I called HIMS & HERS CEO Andrew DUDUM, investors will start to inform the investors that they need to find alternative options for commercial medications in the future or two months.
Still, he and she have Another way to explore. The company allows you to continue to provide more personalized Semaglutide formulations and convert focuses into spherical general weight loss drugs.
Also, Tuesday, Bank of America Securities (Securities)BAC) Analyst Allen Lutz has the price target of him and her company $ 1 to $ 22 (especially $ 12 than the opening price of the stock that day, Lutz maintained a “low performance” (sales) rating.
